ASHMPN2023
“Among the high-risk splicing mutations, SRSF2 has the worst prognostic role,” Dr. Braish and colleagues wrote.
The REVEAL study identified five risk factors, including leukocytosis, duration of time with PV, and more.
The treatment led to reduced hepcidin levels when used alone or in combination with ruxolitinib.
Advertisement
Dr. Al-Ali covers data on combined BET and JAK inhibition for patients with myelofibrosis presented at the 2023 ASH Meeting.
Worse survival in single-hit TP53 patients was mainly driven by bone marrow fibrosis.
Tasquinimod inhibited interaction of A9, a protein associated with poor prognosis.
Advertisement
DT2216 alone was effective, but exhibited a slightly greater cell viability reduction when combined with other therapies.
Subjectivity of morphological assessment and overlapping pathological features of subtypes can hamper accurate MPN diagnosis.
Bomedemstat is an oral lysine-specific demethylase-1 (LSD1) inhibitor clinically active in patients with MPNs.
The study aimed to address “a substantial unmet need for therapies that alter disease trajectory" in patients with MF.
Researchers analyzed PV patients allocated to the ropeginterferon alfa-2b arm of the PROUD-PV/CONTINUATION-PV studies.
The use of combination therapies including XPO1 inhibitor selinexor is a potentially effective therapeutic strategy in MF.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.